Viewing data from:

BIMATOPROST

ANDA

BIMATOPROST | A202719 | SANDOZ INC

1 strength0 unique patents0 unique exclusivities

Reference Listed Drug: LATISSE(TE code: AT)

Hatch-Waxman Litigation

1 case on OB patents from PACER

Case	Court	Filed	Status	Judge
ALLERGAN, INC. v. APOTEX INC., et al 1:2012cv00247 4 patentsANDA 201894, 202719, 203051bimatoprost	NCMD	2012-03-13	Terminated 2015-01-20	—

Source: PACER. NOS 835 (Patent - Abbreviated New Drug Application).

API Supply Chain13 active DMFs1 inactive

13 active API suppliers hold Drug Master Files for this ingredient.

JOHNSON MATTHEY PHARMA SERVICESBIMATOPROST (3077.E)

DMF 209112007

CHIROGATE INTERNATIONAL INCBIMATOPROST

DMF 213822008

KYOWA PHARMA CHEMICAL CO LTDBIMATOPROST DRUG SUBSTANCE

DMF 216812008

EVERLIGHT CHEMICAL INDUSTRIAL CORPBIMATOPROST

DMF 220802008

INDUSTRIALE CHIMICA SRLBIMATOPROST

DMF 234802010

CAYMAN PHARMA SROBIMATOPROST

DMF 243532011

YS LIFE SCIENCE CO LTDBIMATOPROST

DMF 249062011

C-SQUARED PHARMA LTDBIMATOPROST

DMF 259032012

MSN LABORATORIES PRIVATE LTDBIMATOPROST [ROUTE CODE - "BM"]

DMF 270442013

SCINOPHARM TAIWAN LTDBIMATOPROST

DMF 272172013

EUROAPI HUNGARY LTDBIMATOPROST

DMF 295602015

FDC LTDBIMATOPROST USP

DMF 403502024

NEWCHEM SPABIMATOPROST

DMF 418902025

LUPIN LTDInactiveBIMATOPROST

DMF 268772013

Source: FDA Drug Master Files (fda.gov). Type II API DMFs matched by ingredient.

Products (1)

#001 — 0.03%

0 patents0 exclusivities▴

SOLUTION/DROPS;TOPICAL | Approved: Apr 19, 2016

No patent or exclusivity listings for this strength.